最近鉴定慢性糖尿病并发症的治疗方法的努力导致发现了一系列新的高效和选择性的(2-芳基氨基甲酰基-苯氧基)乙酸醛糖还原酶抑制剂。化合物类别的特征是核心模板,该模板利用分子内氢键将药效基团的关键结构元件定位在构象中,从而促进了高结合亲和力。铅候选物,例如40,5-氟-2-(4-溴-2-氟-苄硫代氨基甲酰基)-苯氧基乙酸,抑制醛糖还原酶,IC(50)为30 nM,而对醛还原酶的活性低1100倍,是一种与活性醛解毒有关的酶。另外,实施例40在4天STZ诱导的糖尿病大鼠模型中以31mg / kg / d po的ED(50)降低了神经山梨糖醇水平。
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
thio-evodiamine (66c) showed excellent in vitro and in vivo antitumor efficacy with good tolerability and low toxicity. Antitumor mechanism and target profiling studies indicate that compound 66c is the first-in-class triple topoisomerase I/topoisomerase II/tubulin inhibitor. Overall, this study provided an effective strategy for natural product-based drug discovery.
by introducing a phenolicgroup and phenyl ring to 3,5-diaryl substituents oxadiazole. Structure-activity relationship (SAR) analysis showed that compounds with alkyl groups or with substituents at the 3-position possessed better protective effects. Among the derivatives, 3,5-dimethyl substitutedcompound 24 exhibited the best neuroprotective effect with weak cytotoxicity. Compound 24 possessed a high
[EN] BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB)<br/>[FR] DÉRIVÉS DE BENZAMIDE ET DE NAPHTAMIDE INHIBANT LE FACTEUR NUCLÉAIRE KAPPA(B) (NF-KB)
申请人:PROFECTUS BIOSCIENCES INC
公开号:WO2010127058A1
公开(公告)日:2010-11-04
The invention relates to compounds of formula (1) and formula (2), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries, wherein R1 is defined herein.